Oliver Kacelnik

Oliver Kacelnik

Auto-generated profile, based on publicly available information

Oliver Kacelnik

Department of Antibiotic Resistance and Infection Prevention, Norwegian Institute of Public Health, Oslo, Norway

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PEPetter Elstrøm
Petter Elstrøm
EAElisabeth Astrup
Elisabeth Astrup
KHKristin Hegstad
Kristin Hegstad
ØSØrjan Samuelsen
Ørjan Samuelsen
HEHege Enger
Hege Enger
OKOliver Kacelnik
Oliver Kacelnik
Scandinavian countries have traditionally had a low prevalence of resistant organisms, but have in recent years experienced a change in their epidemiology. We aim to describe the epidemiology of carbapenemase-producing organisms (CPOs), vancomycin-resistant enterococci (VRE) and methicillin-resistant S. aureus (MRSA) in Norway, measure the importance of infections contracted abroad, and assess the morbidity and mortality associated with these resistant bacteria in Norway. We used data from the Norwegian surveillance system for communicable diseases covering all findings of the selected resistant bacteria including both infections and colonisation, in the period 2006–2017. Annual trends were assessed using negative binomial regression. For MRSA, we were able to calculate the Morisita-Horn index and transmission numbers following importation in order to assess the effect this had on further domestic transmission. The incidence rates (per 100,000 personyears) of the three groups of resistant bacteria have increased during the period. In 2017 the incidence rates were 0.82 for CPOs, 7.09 for VRE and 43.8 for MRSA. 81% of CPO cases were diagnosed in hospitals, but 73% were infected abroad. Most VRE cases were infected in Norwegian hospitals, 85% were associated with hospitals outbreaks. MRSA was predominantly diagnosed in the community, only 21% were diagnosed in hospitals. Of all MRSA cases, 35% were infected in other countries. Most MRSA spa-types were not identified again after introduction, resulting in a transmission of MRSA equivalent to a mean of 0.30 persons infected from each spa-type identified (range: 0–22). The proportion of infections among all notified cases within each diagnose was 44% for MRSA, 9% for VRE and 45% for CPOs. Among persons notified with bacteraemia, the 30 days all-cause mortality were 20%, 16% and 50% for MRSA, VRE and CPOs respectively. The incidence rates of CPOs, VRE and MRSA in Norway are low, but increasing. The continuing increase of notified resistant bacteria highlights the need for a revision of existing infection prevention and control guidelines.

5 May 2022 in Eurosurveillance
Verified
Journal Article
Open access
KGKirsten Gravningen
Kirsten Gravningen
OKOliver Kacelnik
Oliver Kacelnik
ELEgil Lingaas
Egil Lingaas
TPTorunn Pedersen
Torunn Pedersen
BIBjørn G Iversen
Bjørn G Iversen
TGthe Pseudomonas outbreak group
the Pseudomonas outbreak group
In November 2021, a clonal outbreak of Pseudomonas aeruginosa of novel sequence type ST3875 was detected in three patients who died of bloodstream infections in one hospital. By 25 April 2022, the outbreak included 339 cases from 38 hospitals across Norway. Initial hospital reports indicate Pseudomonas infection as the main contributing cause in seven deaths. In March 2022, the outbreak strain was identified in non-sterile pre-moistened disposable washcloths, used to clean patients, from three lots from the same international manufacturer.

6 July 2023 in Eurosurveillance
Verified
Journal Article
Open access
PLPaul Christoffer Lindemann
Paul Christoffer Lindemann
TPTorunn Pedersen
Torunn Pedersen
DODorthea Hagen Oma
Dorthea Hagen Oma
JJJessin Janice
Jessin Janice
FGFredrik Grøvan
Fredrik Grøvan
ØSØrjan Samuelsen
Ørjan Samuelsen
Infections with OXA-244-carbapenemase-producing Escherichia coli with sequence type (ST)38 have recently increased in Europe. Due to its low-level activity against carbapenems, OXA-244 can be difficult to detect. Previous assessments have not revealed a clear source and route of transmission for OXA-244-producing E. coli, but there are indications of non-healthcare related sources and community spread. Here we report a hospital-associated outbreak of OXA-244-producing E. coli ST38 involving three hospitals in Western Norway in 2020. The outbreak occurred over a 5-month period and included 12 cases identified through clinical (n = 6) and screening (n = 6) samples. The transmission chain was unclear; cases were identified in several wards and there was no clear overlap of patient stay. However, all patients had been admitted to the same tertiary hospital in the region, where screening revealed an outbreak in one ward (one clinical case and five screening cases). Outbreak control measures were instigated including contact tracing, isolation, and screening; no further cases were identified in 2021. This outbreak adds another dimension to the spread of OXA-244-producing E. coli ST38, illustrating this clone’s ability to establish itself in the healthcare setting. Awareness of challenges concerning OXA-244-producing E. coli diagnostic is important to prevent further spread.

19 December 2023 in Microbial Genomics
Verified
Journal Article
Open access
MRMushtaq Al Rubaye
Mushtaq Al Rubaye
JJJessin Janice
Jessin Janice
JBJørgen Vildershøj Bjørnholt
Jørgen Vildershøj Bjørnholt
OKOliver Kacelnik
Oliver Kacelnik
BHBjørg C Haldorsen
Bjørg C Haldorsen
KHKristin Hegstad
Kristin Hegstad
Between 2010 and 2015 the incidence of vancomycin-resistant Enterococcus faecium (VREfm) in Norway increased dramatically. Hence, we selected (1) a random subset of vancomycin-resistant enterococci (VRE) from the Norwegian Surveillance System for Communicable Diseases (2010–15; n=239) and (2) Norwegian vancomycin-susceptible E. faecium (VSEfm) bacteraemia isolates from the national surveillance system for antimicrobial resistance in microbes (2008 and 2014; n=261) for further analysis. Whole-genome sequences were collected for population structure, van gene cluster, mobile genetic element and virulome analysis, as well as antimicrobial susceptibility testing. Comparative genomic and phylogeographical analyses were performed with complete genomes of global E. faecium strains from the National Center for Biotechnology Information (NCBI) (1946–2022; n=272). All Norwegian VREfm and most of the VSEfm clustered with global hospital-associated sequence types (STs) in the phylogenetic subclade A1. The vanB2 subtype carried by chromosomal Tn1549 integrative conjugative elements was the dominant van type. The major Norwegian VREfm cluster types (CTs) were in accordance with concurrent European CTs. The dominant vanB-type VREfm CTs, ST192-CT3/26 and ST117-CT24, were mostly linked to a single hospital in Norway where the clones spread after independent chromosomal acquisition of Tn1549. The less prevalent vanA VRE were associated with more diverse CTs and vanA carrying Inc18 or RepA_N plasmids with toxin–antitoxin systems. Only 5 % of the Norwegian VRE were Enterococcus faecalis, all of which contained vanB. The Norwegian VREfm and VSEfm isolates harboured CT-specific virulence factor (VF) profiles supporting biofilm formation and colonization. The dominant VREfm CTs in general hosted more virulence determinants than VSEfm. The phylogenetic clade B VSEfm isolates (n=21), recently classified as Enterococcus lactis , harboured fewer VFs than E. faecium in general, and particularly subclade A1 isolates. In conclusion, the population structure of Norwegian E. faecium isolates mirrors the globally prevalent clones and particularly concurrent European VREfm/VSEfm CTs. Novel chromosomal acquisition of vanB2 on Tn1549 from the gut microbiota, however, formed a single major hospital VREfm outbreak. Dominant VREfm CTs contained more VFs than VSEfm.

6 July 2023 in Eurosurveillance
Verified
Journal Article
Open access
OLOskar Ljungquist
Oskar Ljungquist
BHBjørg Haldorsen
Bjørg Haldorsen
APAnna Kaarina Pöntinen
Anna Kaarina Pöntinen
JJJessin Janice
Jessin Janice
EJEllen Haldis Josefsen
Ellen Haldis Josefsen
ØSØrjan Samuelsen
Ørjan Samuelsen
Introduction: National and regional carbapenemase-producing Enterobacterales (CPE) surveillance is essential to understand the burden of antimicrobial resistance, elucidate outbreaks, and develop infection-control or antimicrobial-treatment recommendations. Aim: This study aimed to describe CPE and their epidemiology in Norway from 2015 to 2021. Methods: A nationwide, population-based observational study of all verified clinical and carriage CPE isolates submitted to the national reference laboratory was conducted. Isolates were characterised by antimicrobial susceptibility testing, whole genome sequencing (WGS) and basic metadata. Annual CPE incidences were also estimated. Results: A total of 389 CPE isolates were identified from 332 patients of 63 years median age (range: 0–98). These corresponded to 341 cases, 184 (54%) being male. Between 2015 and 2021, the annual incidence of CPE cases increased from 0.6 to 1.1 per 100,000 person-years. For CPE-isolates with available data on colonisation/infection, 58% (226/389) were associated with colonisation and 38% (149/389) with clinical infections. WGS revealed a predominance of OXA-48-like (51%; 198/389) and NDM (34%; 134/389) carbapenemases in a diversified population of Escherichia coli and Klebsiella pneumoniae, including high-risk clones also detected globally. Most CPE isolates were travel-related (63%; 245/389). Although local outbreaks and healthcare-associated transmission occurred, no interregional spread was detected. Nevertheless, 18% (70/389) of isolates not directly related to import points towards potentially unidentified transmission routes. A decline in travel-associated cases was observed during the COVID-19 pandemic. Conclusions: The close-to-doubling of CPE case incidence between 2015 and 2021 was associated with foreign travel and genomic diversity. To limit further transmission and outbreaks, continued screening and monitoring is essential.

29 April 2022 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
IEIngeborg Hess Elgersma
Ingeborg Hess Elgersma
KTKjetil Telle
Kjetil Telle
PEPetter Elstrøm
Petter Elstrøm
HSHåvard Skagseth
Håvard Skagseth
OKOliver Kacelnik
Oliver Kacelnik
Background:Understanding and limiting infection in healthcare workers (HCWs) and subsequent transmission to their families is always important and has been underscored during the COVID-19 pandemic. Except in specific and local settings, little is known about the extent of such transmissions at the national level.Objective:To describe SARS-CoV-2 infection in HCWs and to estimate the risk of HCWs transmitting COVID-19 to their household members, including calculating the secondary attack rate to household members and estimating the risk for hospital workers to contract COVID-19 at home.Methods:Using individual-level data on all HCWs employed in Norwegian hospitals and their household members, we identified (1) the number of HCWs who tested positive for SARS-CoV-2 between August 2020 and September 2021 and the proportion of those who were index cases in their own household and (2) the number of HCWs who were secondary cases in their own households.Results:During this period, ∼3,005 (2,6%) hospital workers acquired COVID-19. Almost half of all hospital workers with confirmed COVID-19 were likely index cases in their own households. When the index case in a family was an HCW, the secondary attack rate was 24.8%. At least 17.8% of all confirmed COVID-19 cases among hospital workers were acquired in the household.Conclusions:Our results suggest not only that many HCWs are infected with SARS-CoV-2 in their households but also that infected HCWs constitute a serious infection risk to members of the HCW’s household.